Baxter International (WBO:BAX) EBIT: €-186 Mil (TTM As of Mar. 2026)


WBO:BAX Baxter International Inc WBO:BAX
56 GF Score
Price €18.38
GF Value €28.97
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Baxter International EBIT?

Baxter International WBO:BAX +4.49% 56 EBIT is €-186 Mil as of Mar. 2026. GuruFocus rates WBO:BAX with a GF Score™ of 56/100 and a GF Value™ of €28.97 (Possible Value Trap). The stock has 6 warning signs investors should review.

Baxter International's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €62 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €-186 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Baxter International's annualized ROC % for the quarter that ended in Mar. 2026 was 1.72%. Baxter International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.63%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Baxter International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1.14%.


Baxter International  (WBO:BAX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Baxter International's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=228.36 * ( 1 - 0% )/( (13584.578 + 12955.97)/ 2 )
=228.36/13270.274
=1.72 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17126.97 - 1863.428 - ( 1678.964 - max(0, 2536.38 - 5868.688+1678.964))
=13584.578

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=17166.79 - 2466.115 - ( 1744.705 - max(0, 3194.445 - 5922.655+1744.705))
=12955.97

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Baxter International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=249.12/( ( (2720.844 + max(1664.446, 0)) + (2759.35 + max(1711.835, 0)) )/ 2 )
=249.12/( ( 4385.29 + 4471.185 )/ 2 )
=249.12/4428.2375
=5.63 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1589.294 + 1906.128 + 633.668) - (1863.428 + 120.414 + 480.802)
=1664.446

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1468.77 + 2003.34 + 705.84) - (2466.115 + 0 + 4.5474735088646E-13)
=1711.835

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Baxter International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-185.655/16267.064
=-1.14 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Baxter International EBIT Related Terms


Baxter International EBIT Historical Data

* Premium members only.

The historical data trend for Baxter International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baxter International EBIT Chart

Baxter International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,170.86 -2,676.24 687.75 113.65 -183.61

Baxter International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.15 177.74 161.03 -586.70 62.28

WBO:BAX vs COO, ATR, RGEN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Baxter International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxter International EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Baxter International's EV-to-EBIT falls into.


WBO:BAX
56GF Score
Baxter International Inc WBO:BAX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Baxter International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-186 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-186 Mil mean?
Baxter International (WBO:BAX) has a EBIT of €-186 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Baxter International.
Is Baxter International's EBIT too high?
Baxter International's current EBIT is €-186 Mil. Overall, Baxter International has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Baxter International's EBIT compare to COO and ATR?
Baxter International's EBIT of €-186 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Baxter International. Baxter International's current EBIT is €-186 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (WBO:BAX) is currently considered Possible Value Trap. The stock's GF Value™ is €28.97, compared to a current price of €18.38 — trading 36.6% below its estimated fair value. The current EBIT is €-186 Mil. Baxter International's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Baxter International (WBO:BAX), the current EBIT is €-186 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Baxter International (WBO:BAX) Overvalued in 2026?

Based on GuruFocus' analysis, Baxter International stock appears to be undervalued. The current stock price of €18.38 is trading 36.6% below its estimated GF Value™ of €28.97. GuruFocus considers Baxter International to be Possible Value Trap.

Key valuation signals for WBO:BAX:

  • EBIT: €-186 Mil
  • GF Value™: €28.97 vs. price of €18.38 (36.6% below fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the WBO:BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Baxter International Business Description

Address One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
56GF Score

Get the complete analysis for WBO:BAX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.38
Price
€28.97
GF Value